Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA) Insider Trading
Directors, officers and holders of more than 10% of OLMA report their trades in its stock on SEC Form 4, within two business days. Each row below is one Form 4 transaction line. The one-letter code says what kind of transaction it was: only P (purchase) and S (sale) are open-market or private trades; awards, option exercises, tax withholding and gifts carry other codes.
Recent Form 4 transactions
The 50 most recent of 147 transactions on file: 0 with code P, 15 with code S and 35 with other codes.
| Date | Insider | Title | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | O'Byrne Jason | CHIEF FINANCIAL OFFICER | A Award | 650,000 | Not measured | Not measured |
| Jul 24, 2026 | Harmon Cyrus | Director | S Sale | 12,500 | $11.71 | $146,425 |
| Jul 23, 2026 | Harmon Cyrus | Director | S Sale | 12,500 | $11.58 | $144,738 |
| Jun 18, 2026 | BVF PARTNERS L P/IL | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | BUTITTA CYNTHIA M | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | Horning Sandra | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | Graham G. Walmsley | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | CLARK IAN T | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | Harmon Cyrus | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | Hrustanovic Gorjan | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | Garland J. Scott | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | Larson Yi | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | Raman Prakash | Director | A Award | 29,500 | Not measured | Not measured |
| Jun 18, 2026 | RAPPAPORT ANDREW | Director | A Award | 29,500 | Not measured | Not measured |
| Apr 28, 2026 | Raman Prakash | Director | A Award | 24,150 | Not measured | Not measured |
| Apr 28, 2026 | Raman Prakash | Director | A Award | 2,911 | Not measured | Not measured |
| Mar 4, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | S Sale | 24,767 | $24.25 | $600,600 |
| Mar 4, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise | 25,000 | $4.37 | $109,250 |
| Mar 4, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise | 25,000 | Not measured | Not measured |
| Mar 4, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | S Sale | 233 | $24.69 | $5,753 |
| Mar 3, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise | 15,000 | Not measured | Not measured |
| Mar 3, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | S Sale | 15,000 | $23.01 | $345,150 |
| Mar 3, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise | 15,000 | $4.37 | $65,550 |
| Feb 2, 2026 | Austin Sasha Lu | VP of Finance and Controller | A Award | 11,700 | Not measured | Not measured |
| Feb 2, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | A Award | 56,250 | Not measured | Not measured |
| Feb 2, 2026 | Bohen Sean | PRESIDENT AND CEO | A Award | 850,000 | Not measured | Not measured |
| Feb 2, 2026 | Austin Sasha Lu | VP of Finance and Controller | A Award | 29,250 | Not measured | Not measured |
| Feb 2, 2026 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award | 106,250 | Not measured | Not measured |
| Feb 2, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | A Award | 250,000 | Not measured | Not measured |
| Feb 2, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | A Award | 106,250 | Not measured | Not measured |
| Feb 2, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | A Award | 220,000 | Not measured | Not measured |
| Feb 2, 2026 | Bohen Sean | PRESIDENT AND CEO | A Award | 275,000 | Not measured | Not measured |
| Feb 2, 2026 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award | 250,000 | Not measured | Not measured |
| Jan 20, 2026 | Harmon Cyrus | Director | S Sale | 10,000 | $26.88 | $268,800 |
| Jan 15, 2026 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | S Sale | 100,000 | $28.73 | $2,873,000 |
| Jan 14, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | M Exercise | 50,000 | $4.87 | $243,500 |
| Jan 14, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S Sale | 14,997 | $28.60 | $428,914 |
| Jan 14, 2026 | Harmon Cyrus | Director | S Sale | 3,489 | $29.12 | $101,600 |
| Jan 14, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | M Exercise | 50,000 | Not measured | Not measured |
| Jan 14, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S Sale | 35,003 | $28.99 | $1,014,737 |
| Jan 13, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | M Exercise | 50,000 | Not measured | Not measured |
| Jan 13, 2026 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | S Sale | 3,822 | $28.01 | $107,054 |
| Jan 13, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S Sale | 49,800 | $27.60 | $1,374,480 |
| Jan 13, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S Sale | 200 | $28.49 | $5,698 |
| Jan 13, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | M Exercise | 50,000 | $4.87 | $243,500 |
| Jan 12, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S Sale | 10,000 | $28.34 | $283,400 |
| Dec 26, 2025 | Bohen Sean | PRESIDENT AND CEO | G Gift | 8,500 | Not measured | Not measured |
| Dec 23, 2025 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | S Sale | 99,509 | $27.66 | $2,752,419 |
| Dec 23, 2025 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 50,000 | $7.02 | $351,000 |
| Dec 23, 2025 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 50,000 | Not measured | Not measured |
The full Form 4 history is on the OLMA company page (Insider Trades card, View all).
Questions about this data
Which insider transactions are open-market trades?
Code P (open market or private purchase) and code S (open market or private sale). Code F is shares withheld to pay tax on vesting stock, A is an award from the company, M and X are option exercises and G is a gift. None of those is the insider choosing to buy or sell in the market.
How quickly are insider trades reported?
A Form 4 is due before the end of the second business day after the trade. The date shown is the transaction date from the form.
Who has to file Form 4?
Officers, directors and beneficial owners of more than 10% of a class of the company’s registered equity, under Section 16 of the Securities Exchange Act.
Look up any code in the Form 4 transaction code reference, or read Form 4 codes explained.